Inaxaplin Shows Kidney Benefit In Additional Patient Groups As Vertex Completes Key Trial Enrollment

Vertex Pharmaceuticals reported positive Phase 2b results for inaxaplin in additional patient groups with APOL1-mediated kidney disease. The company also completed enrollment for its ongoing Phase 2/3 AMPLITUDE trial, advancing a key clinical development program toward potential later-stage data and regulatory milestones.